Edition:
United States

Prima BioMed Ltd (PRR.AX)

PRR.AX on Australia Stock Exchange

0.03AUD
21 Jul 2017
Change (% chg)

$0.00 (+8.70%)
Prev Close
$0.02
Open
$0.02
Day's High
$0.03
Day's Low
$0.02
Volume
2,555,686
Avg. Vol
1,717,088
52-wk High
$0.04
52-wk Low
$0.02

Latest Key Developments (Source: Significant Developments)

Prima Biomed enters securities purchase agreement to purchase 2.6 mln of its American Depositary shares
Thursday, 29 Jun 2017 07:28pm EDT 

June 30 (Reuters) - Prima Biomed Ltd :Entered into a securities purchase agreement with certain accredited investors to purchase 2.6 million of its american depositary shares.Total gross proceeds of approximately us$5.0 million.To purchase its american depositary shares at a purchase price of us$1.90 per ads in a registered direct offering.Prima intends to use net proceeds from this offering to continue ongoing clinical development of imp321.  Full Article

Prima Biomed announces pricing of direct offering of its American Depositary Shares
Thursday, 29 Jun 2017 11:34am EDT 

June 29 (Reuters) - Prima Biomed Ltd :Prima Biomed Ltd announces pricing of $5.0 million registered direct offering of its American depositary shares.Prima Biomed - Entered into a securities purchase agreement with certain accredited investors to purchase 2.6 million of its American depositary shares at $1.90 per ADS.Prima Biomed - In a concurrent private placement, co agreed to issue unregistered warrants to purchase up to 1,973,451 of its ADS.Prima Biomed - The warrants have an exercise price of $2.50 per ADS, are exercisable immediately and will expire 5.5 years from the date of issuance.  Full Article

Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer
Wednesday, 21 Dec 2016 04:33pm EST 

Prima BioMed Ltd : Prima BioMed Ltd - data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells . Prima BioMed Ltd - IMP321 is safe and well tolerated . Prima BioMed Ltd - subject to confirmation of dose escalation committee on 30 Dec, Prima will now commence randomised phase of trial in January 2017 . Prima BioMed Ltd - patients will receive paclitaxel treatment plus placebo or paclitaxel in conjunction with imp321 .Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer.  Full Article

Prima signs MOU with WuXi
Tuesday, 22 Nov 2016 08:15pm EST 

Prima Biomed Ltd - : WuXi & Prima sign MOU for strategic partnership .Mou was signed to form a strategic biologics development and manufacturing partnership.  Full Article

Prima signs MOU with WuXi
Tuesday, 22 Nov 2016 06:14pm EST 

Prima Biomed Ltd - : WuXi & Prima sign MOU for strategic partnership .Mou was signed to form a strategic biologics development and manufacturing partnership.  Full Article

Prima Biomed enters agreement with Sydys to advance CVac Program
Thursday, 12 May 2016 03:26am EDT 

Prima BioMed Ltd : PRR enters agreement with Sydys to Advance Cvac Program . In the spin out transaction Prima will receive a 9.9% equity stake in sydys at closing as consideration for the assets being transferred . Prima could receive over A$400 million for achievement of set commercial sales targets, in addition to single digit royalties on sales .  Full Article

Prima BioMed Ltd gains Belgian regulatory approval to commence IIB study of IMP321
Monday, 26 Oct 2015 08:44pm EDT 

Prima BioMed Ltd:Prima Biomed gains Belgian regulatory approval to commence a registration phase IIB study of imp321.Says imp321 phase IIB trial initiation is expected before the end of 2015.  Full Article

Prima BioMed announces investment from Nyenburg
Tuesday, 13 Oct 2015 01:38am EDT 

Prima BioMed Ltd:Has raised about A$1.55 mln via a placement of shares at A$0.05 per share to Nyenburgh Investment Partners (NYIP).The proceeds from the Placement will be used to fund Prima's IMP321 clinical trial program and provide additional working capital.  Full Article

BRIEF-Prima BioMed announces second milestone payment for IMP701 program

* it will receive a second undisclosed significant clinical milestone payment from Novartis